RVL Pharmaceuticals plc Sustainability Profile
RVL Pharmaceuticals plc, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for eye care. Founded in 2018, the company has quickly established itself as a leader in the development of unique ophthalmic products, notably its flagship treatment, Upneeq, which addresses acquired ptosis. With a focus on enhancing patient outcomes, RVL Pharmaceuticals is dedicated to advancing the field of ophthalmology through cutting-edge research and development. The company has achieved significant milestones, including successful product launches and strategic partnerships that bolster its market position. As RVL continues to expand its operational footprint, it remains committed to delivering high-quality, effective solutions that meet the evolving needs of healthcare professionals and patients alike.
DitchCarbon Score
How does RVL Pharmaceuticals plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RVL Pharmaceuticals plc's score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RVL Pharmaceuticals plc's reported carbon emissions
RVL Pharmaceuticals plc, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that RVL Pharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for RVL Pharmaceuticals to develop and communicate its climate strategy to align with industry standards and stakeholder expectations.
How Carbon Intensive is RVL Pharmaceuticals plc's Industry?
How Carbon Intensive is RVL Pharmaceuticals plc's Location?
RVL Pharmaceuticals plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
RVL Pharmaceuticals plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
